Автор: Umida Категория: Статьи (кафедра)
Дата публикации Просмотров: 1656
Печать

Z.A.Olimova1,S.N.Navruzov2, D.A.Pulatov3, G.J.Hakimova.4

 Medical oncology department. National Research Center of Oncology.  Farabiy street, Tashkent. UZBEKISTAN

'Metronomic' chemotherapy for the palliative treatment of advanced breast cancer.

Background:The aim of the present study was to compare the effectiveness of cyclophosphamide-methotrexate ‘metronomic’ chemotherapy with the same regimen plus Imatinib in the palliative treatment of patients with metastatic breast cancer. Metronomic chemotherapy-the chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule of administration at close regular intervals, with no prolonged drug-free breaks-is a potentially novel approach to the control of advanced cancer disease.

 Patients and methods: Patients with advanced breast cancer were randomized to receive oral C (cyclophosphamide 50 mg daily) and M (methotrexate 2.5 mg twice daily on days 1 and 4) (arm A) or the same regimen plus Imatinib (400 mg daily) (arm B).

Results: In 171 evaluable patients we observed seven complete remissions (CR) in both arms A and B, 7 partial remission (PR) in arm A and 15 in arm B, for an overall response of 11.8% (95% confidence interval (CI) 5.8% to 20.6%) in arm A and 20.9% [95% CI 12.9% to 31%] in arm B. The clinical benefit (CR + PR + SD ≥ 24 weeks) was 41.5% for B arms. Toxicity was generally mild. Neurological toxicity (2% versus 5%; P < 0.0001) and constipation (8% versus 13%; P < 0.0001) was observed in both arm.

Conclusions: Metronomic low-dose CM with Imatinib combination was effective and minimally toxic. The addition of Imatinib improves results.

                                                                     

 

 

joomla 1.8 joomla 1.8